Table 2.

FXI inhibitors currently under clinical development for the treatment of TEV and AF.

Compound Name	Developer	Target	Inhibitory Class	Phase of Development	Population	Trial Design	Number of Patients	Ref.
Abelacimab (MAA868)	Anthos Therapeutics Novartis AG	FXI and FXIa	Fully human mAb IgG1	Phase 1	Healthy volunteers and patents with AF	Randomized, subject-and investigator-blinded, placebo-controlled study	18	[22]
				Phase 2	Patients undergoing total knee arthroplasty	Open-label, parallel-group trial	412	[23]
Osocimab (BAY1213790)	Bayer Pharmaceuticals	FXIa	Fully human mAb IgG1	Phase 1	Healthy volunteers	Randomized, single-blind, placebo-controlled, dose-escalation study	81	[24]
				Phase 2	Patients undergoing total knee arthroplasty	Randomized, open-label, adjudicator-blinded, noninferiority trial	813	[25]
BAY1831865	Bayer Pharmaceuticals	FXI	Humanized mAb IgG1	Phase 1	Healthy volunteers	Randomized, single-blind (participant), parallel-group, placebo-controlled, dose-escalation	70	[26]
AB023/ Xisomab 3G3	Aronora	FXIa	Fully human monoclonal IgG1 antibody	Phase 1	Healthy volunteers	Randomized, double-blind, placebo-controlled, single ascending bolus dose study	21	[27]
				Phase 2	Patients with end stage renal disease on chronic hemodialysis	Randomized, Double-Blind, Placebo-Controlled Study	24	[28]
Asundexian (BAY 2433334)	Bayer Pharmaceuticals	FXIa	Small molecule	Phase 1	Healthy volunteers	Single-blind, placebo-controlled, dose-escalation study	70	[29]
				Phase 2	Patients with AF	Randomized, double-blind, double-dummy, dose-finding	755	[30]
				Phase 2	Patients with	Randomized, placebo-controlled, double-blind, parallel-group, dose-finding	1601	[31]
Milvexian (BMS-986177 JNJ- 70033093)	Janssen of Johnson and Johnson and Bristol-Myers Squibb	FXIa	Small molecule	Phase 1	Healthy and mild or moderate hepatic impairment	Open-label	26	[32]
				Phase 1	Healthy volunteers	Randomized, double-blind, placebo-controlled, single and multiple ascending doses	94	[33]
				Phase 2	Patients undergoing total knee arthroplasty	Randomized, parallel-group	1242	[34]
				Phase 2	Patients with ischemic stroke	Randomized, double-Blind, placebo-controlled, dose-Ranging Study	2366	[35]
Fesomersen (IONIS-FXI-LRX)	IONIS and Bayer	FXIa	Antisense Oligonucleotide	Phase 1	Healthy volunteers	Placebo-controlled, dose escalation study	36	[36]
				Phase 1	End-Stage Renal Disease on Hemodialysis patients	Open-label single-dose and double-blind multiple doses	49	[37]
				Phase 2	Patients with end stage renal disease on chronic hemodialysis	Double-blind, randomized	43	[38]
				Phase 2	Patients undergoing total knee arthroplasty	open-label, parallel-group	300	[39]

AF: atrial fibrillation; F: factor; Ig: Immunoglobulin.